BioCentury
ARTICLE | Clinical News

BTI-320: Phase II start

March 10, 2014 7:00 AM UTC

This month, Boston Therapeutics will begin a double-blind, placebo-controlled, 3-way crossover, U.S. Phase II trial to evaluate BTI-320 for 3 months in 24 Type II diabetics who are being treated with ...